Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations
https://finance.yahoo.com/news/electromedical-technologies-announces-preliminary-unaudited-121900011.html
$SGTM Orlando, FL, April 18, 2023 (GLOBE NEWSWIRE) -- The Sustainable Green Team, LTD. (OTCQX: SGTM) (“SGTM” or the “Company”), a provider of environmentally conscious solutions in the arbor care, disposal, and recycling industries reports audited fiscal 2022 year end results (fiscal year ended December 31, 2022) and announces its first Annual Shareholder Meeting, to be held May 12, 2023, 9:00am Eastern Time.
https://www.marketwatch.com/press-release/the-sustainable-green-team-ltd-reports-355m-in-revenue-and-1203m-in-assets-for-its-fiscal-2022-audited-ye-and-announces-its-first-annual-shareholder-meeting-2023-04-18?mod=mw_quote_news_seemore
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations
https://finance.yahoo.com/news/electromedical-technologies-announces-preliminary-unaudited-121900011.html
$EMED As the Company moves closer to production of the new next-generation flagship device, management plans to offer a special upgrade and exchange program to existing clients, which will be bundled with a lifetime warranty.
$EMED
The WellnessPro Plus®
triggers our body’s natural processes. Electrical impulses travel from nerves around the injured area to our brain, delivering the unpleasant sensation of pain. WellnessPro Plus® operates by disrupting these pain signals received by our synapses, mimicking our natural electric signals to relieve patients from pain.
Electromedical Technologies brought together some of the leading biomedical researchers from around the world to develop next generation TENS machines. Through product innovation and a forward-thinking approach, we succeeded to develop specific algorithms in electrotherapy that work to alleviate pain.
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED Electricity enables information to circulate in the body, electrotherapy manipulates a specific part of the information by pulsating electrical waves interfering with the transmission of pain signals.
Our nervous system is composed of our brain and our spinal cord, which combine to form the central nervous system; and our sensory and motor nerves, which form the peripheral nervous system. Nerves send information about what is happening in our environment to the brain via the spinal cord. The brain then sends information back to our nerves, helping us to perform actions in response. By treating specific body areas and varying frequency, wavelength and intensity applied, electrotherapy devices can manipulate impulses and target actions to alleviate pain or they can disrupt pain signals.
$EMED Despite the benefits of a diverse consumer drug market for pain managment, the non-medical use of pharmaceutical opioids has triggered new health threats & an escalating drug abuse epidemic.
$EMED Electromedical’s commitment to create long-lasting drug-free solutions to pain management is honored by the development of The WellnessPro Plus®, a technologically advanced TENS (transcutaneous electrical nerve stimulation) therapy device focusing on pain relief.
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED In 2018, 67,367 drug overdose deaths occurred in the United States, 70% of them involved opioids.
https://electromedtech.com/investors-relations/
$EMED Bio-electrical stimulation is a safe non toxic pain management therapy that activates the body’s innate
ability to heal itself. Therapy provides targeted pain alleviation to specific areas of the body by
modifying its electrical language related to pain, regulating signals and stimulating endogenous opioids
distributed in the nervous systems, particularly in circuits involved in pain modulation, reward,
responses to stress, and autonomic control.
$EMED Matthew Wolfson, Founder and CEO commented, "Q4 was a breakout quarter. We saw topline sales jump in response to further expansion in our brand awareness and sales & marketing performance. Overall, it was our best quarter since we went public and provides strong market feedback that our next-generation R&D and market positioning represents the start of an exciting new chapter for Electromedical. And the path is only going to get more exciting as we get ready to launch our revolutionary Infinity device."
$EMED Electrotherapy seems to be one of the most promising substitute to toxic and addictive painkillers. Since introducing the WellnessPro+ in 2007, ElectroMedical Technologies has been an innovation pioneer at the forefront of the alternative pain relief movement.
$EMED Electromedical’s commitment to create long-lasting drug-free solutions to pain management is honored by the development of The WellnessPro Plus®, a technologically advanced TENS (transcutaneous electrical nerve stimulation) therapy device focusing on pain relief.
$PVSP Built a solid finance and accounting infrastructure.
$GBHL $PVSP $GBHL via
@Investors_Hub
$PVSP While nobody knows, if you do basic math from all of the publicly available data, current enterprise value of Pervasip (=all Artizen) comes in at around $40 million on a fully diluted basis without any forward-looking value attached;
That is CURRENT value; when the company announces its various licensing and acquisition opportunities, the stock will only go up from there!
$GBHL
$PVSP Twitter Allows Cannabis Ads https://adcann.ca/blog/twitters-new-policy-allows-cannabis
Bullish
$PVSP You must be a Pervasip shareholder of record at the Record Date to take advantage of this double; buying a PVSP share the day after will not transfer to Artizen Corp
$GBHL
$PVSP PERVASIP is in the process of looking for other opportunities to create value.
$PVSP While nobody knows, if you do basic math from all of the publicly available data, current enterprise value of Pervasip (=all Artizen) comes in at around $40 million on a fully diluted basis without any forward-looking value attached;
That is CURRENT value; when the company announces its various licensing and acquisition opportunities, the stock will only go up from there!
$GBHL
$PVSP Holders of Pervasip’s issued and outstanding common shares as of the record date will receive an aggregate of 15,000,000 shares of Artizen common stock, corresponding to 15% of Artizen’s fully diluted issued and outstanding common shares upon completion of the transaction (in addition to retaining their shares in Pervasip). Likewise, holders of Pervasip’s Series K and other convertible securities will receive an aggregate of 85,000,000 shares of Artizen common stock, the vast majority of which will be subject to lock-up restrictions prohibiting sales prior to Artizen’s realization of material growth and other performance objectives. Artizen will have 100,000,000 common shares outstanding on a fully diluted basis upon completion of the transaction, with no convertible debt or other securities.
$GBHL
$PVSP
“Spinning out Artizen will allow us to properly capitalize the business to take advantage of multiple expansion opportunities to build on our existing foundation,” said German Burtscher, Chairman and Chief Executive Officer of Pervasip and Artizen.
$PVSP You must be a Pervasip shareholder of record at the Record Date to take advantage of this double; buying a PVSP share the day after will not transfer to Artizen Corp
$GBHL
$HTSC Here to Serve (HTSC) owns a basket of minority positions in publicly traded equities. It
received these equity positions in exchange for consulting and financial reporting services.
The holdings include:
• 65,000,000 shares of Tamino Minerals Inc (OTC: TINO), which is a gold and lithium
exploration company
• 2,200,000,000 shares of IDGlobal Corp. (OTC: IDGC), which owns its own web-based
intellectual property for energy monitoring
• 1,000,000 shares of Firma Holdings Corp. (OTC: FRMA), which seeks to develop
advanced carbon materials
• 79,000,000 shares of Agri-Dynamics. Inc (OTC: AGDY), which is a gold exploration
company
• 30,000,000 shares of Pervasip Corp. (OTC: PVSP), which is a commercial cannabis
operation in Washington State that produces the 9th best-selling brand in the USA
and preferred stock that is convertible into 30 million shares of common stock of KRTL
Holding Group, Inc. (OTC: KRTL), a psilocybin and hemp research entity.
• An outdoor Hemp License in Iowa.
$PVSP While nobody knows, if you do basic math from all of the publicly available data, current enterprise value of Pervasip (=all Artizen) comes in at around $40 million on a fully diluted basis without any forward-looking value attached;
That is CURRENT value; when the company announces its various licensing and acquisition opportunities, the stock will only go up from there!
$GBHL
100 M shares of Common Stock with NO Debt, No Convertibles, No Special Series Stock, simple and clean share structure, every shareholder get the same type of Common Stock with one vote per share, as it should be.
If you own 1% of PVSP, you will get 1% ownership in Artizen Spin Off. Totally Fair and straight forward.
$PVSP You must be a Pervasip shareholder of record at the Record Date to take advantage of this double; buying a PVSP share the day after will not transfer to Artizen Corp
$PVSP Key Highlights
Instead of focusing on a rollout of licensed Dabs and Vape4Less brands, the Company pursued an outright acquisition of those brands plus others, achieving more beneficial long-term value but not yet realizing respective revenue gains as indicated earlier.
Q3 shows margin improvement over Q2 as higher margin brands and products are coming online, a trend that will continue into Q4 2022.
The Company continues to pursue additional operational, financial, and legal restructuring to further clean and strengthen its balance sheet.
While expensive, the Company will continue to seek capital from available equity or debt sources.
The cannabis market on the Westcoast continues to see a dramatic post-pandemic retraction, creating a challenging environment for all producers, processors, and retailers. With an almost 18% contraction in retail revenues, massive oversupply, sustained downward price pressure and increasing costs, the industry is still months away from a recovery, although the bottom for pricing seems to have been reached.
https://www.morningstar.com/news/globe-newswire/8666987/pervasip-announces-3rd-quarter-financials
$PVSP While nobody knows, if you do basic math from all of the publicly available data, current enterprise value of Pervasip (=all Artizen) comes in at around $40 million on a fully diluted basis without any forward-looking value attached;
That is CURRENT value; when the company announces its various licensing and acquisition opportunities, the stock will only go up from there!
$PVSP
“Spinning out Artizen will allow us to properly capitalize the business to take advantage of multiple expansion opportunities to build on our existing foundation,” said German Burtscher, Chairman and Chief Executive Officer of Pervasip and Artizen.
$PVSP You must be a Pervasip shareholder of record at the Record Date to take advantage of this double; buying a PVSP share the day after will not transfer to Artizen Corp
$PVSP News and Headlines https://www.barchart.com/stocks/quotes/PVSP/news
$PVSP You must be a Pervasip shareholder of record at the Record Date to take advantage of this double; buying a PVSP share the day after will not transfer to Artizen Corp
$PVSP Overview https://www.otcmarkets.com/stock/PVSP/overview
$PVSP While nobody knows, if you do basic math from all of the publicly available data, current enterprise value of Pervasip (=all Artizen) comes in at around $40 million on a fully diluted basis without any forward-looking value attached;
That is CURRENT value; when the company announces its various licensing and acquisition opportunities, the stock will only go up from there!
$PVSP Artizen Spin Off News https://finance.yahoo.com/news/pervasip-announces-artizen-spin-off-141500515.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$PVSP Pervasip previously announced its identification of a series of exciting expansion opportunities, including potential acquisitions involving licensed wholesale and retail operations that would offer Artizen the potential to establish itself as a vertically integrated multi-state operator (“MSO”).
https://www.benzinga.com/markets/cannabis/23/01/30465565/pervasip-announces-artizen-spin-off?utm_campaign=partner_feed&utm_source=MarketWatch&utm_medium=partner_feed&utm_content=site&mod=mw_quote_news
Followers
|
1831
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
185857
|
Created
|
11/20/06
|
Type
|
Premium
|
Moderator The_Pink_Lawyer | |||
Assistants Lunatic $tock_Professor |
WELCOME TO THE NEW 10 BAGGAS - SAME OLD BEAST MODE SINCE 2006
SIGN UP FOR OUR NON-BIASED ALERTS HERE >>>>
(We will not be paid by 3rd party note holders or promoters)
Step By Step Penny Stock Trading Courses - Sign Up HERE |
Posts Today
|
0
|
Posts (Total)
|
185857
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |